Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

被引:0
|
作者
Zhang, Xinyu [1 ,2 ,3 ]
Cao, Chao [1 ,2 ]
Zheng, Fei [1 ,2 ]
Liu, Chang [1 ,2 ]
Tian, Xiuqing [1 ,2 ,3 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, 6699 Qingdao Rd, Jinan City 250117, Peoples R China
关键词
GLP-1; RAs; Cardiovascular; Type; 2; diabetes; Ischemic cardiomyopathy; Diabetic cardiomyopathy; Heart failure; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELL; IMPROVING MITOCHONDRIAL-FUNCTION; LEFT-VENTRICULAR PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; INSULIN-SECRETION; EJECTION FRACTION; CONSCIOUS DOGS; BLOOD-PRESSURE;
D O I
10.1007/s10557-025-07670-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundGlucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.ObjectiveThis review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential.MethodsA comprehensive review was carried out through literature research.Results and DiscussionIn pancreatic beta-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of beta-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients.ConclusionGLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] GLP-1 receptor agonists for type 2 diabetes
    De Block, Christophe E. M.
    Van Gaal, Luc F.
    LANCET, 2009, 374 (9683): : 4 - 6
  • [22] GLP-1 receptor agonists beyond diabetes management
    不详
    ECLINICALMEDICINE, 2024, 78
  • [23] Two New GLP-1 Receptor Agonists for Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1455): : 109 - 111
  • [24] Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings
    Holst, J. J.
    Vilsboll, T.
    DIABETES OBESITY & METABOLISM, 2013, 15 (01): : 3 - 14
  • [25] Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease
    Yang, Xiaoyan
    Feng, Peng
    Ji, Rong
    Ren, Yiqing
    Wei, Wenshi
    Holscher, Christian
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (05) : 445 - 460
  • [27] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Bahtiyar, Gul
    Pujals-Kury, Jean
    Sacerdote, Alan
    CURRENT DIABETES REPORTS, 2018, 18 (10)
  • [28] The potential role of GLP-1 receptor agonists in osteoarthritis
    Ryan, Mackenzie
    Megyeri, Saige
    Nuffer, Wes
    Trujillo, Jennifer M.
    PHARMACOTHERAPY, 2025, 45 (03): : 177 - 186
  • [29] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Gül Bahtiyar
    Jean Pujals-Kury
    Alan Sacerdote
    Current Diabetes Reports, 2018, 18
  • [30] ASSESSING GEROTHERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS
    Newman, John
    INNOVATION IN AGING, 2024, 8 : 140 - 140